Industry
Drug Manufacturers - Specialty & Generic
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
Loading...
Open
7.63
Mkt cap
538M
Volume
608K
High
7.89
P/E Ratio
6.44
52-wk high
12.83
Low
7.32
Div yield
0.08
52-wk low
4.26
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 11:31 am
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 11:33 am
Portfolio Pulse from Chris Katje
August 26, 2024 | 7:58 pm
Portfolio Pulse from Vandana Singh
August 23, 2024 | 6:29 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 8:02 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 8:01 pm
Portfolio Pulse from Michael Juliano
August 19, 2024 | 6:26 pm
Portfolio Pulse from Mark Putrino
August 16, 2024 | 6:17 pm
Portfolio Pulse from Avi Kapoor
August 16, 2024 | 2:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 11:30 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.